Differential effects of the C1431T and Pro12Ala PPARγ gene variants on plasma lipids and diabetes risk in an Asian population Published, JLR Papers in Press, January 16, 2004. DOI 10.1194/jlr.M300363-JLR200
暂无分享,去创建一个
X. Adiconis | E. Tai | D. Corella | J. Ordovás | S. Chew | M. Deurenberg-Yap | C. Tan
[1] C. Bogardus,et al. A functional variant in the peroxisome proliferator-activated receptor gamma2 promoter is associated with predictors of obesity and type 2 diabetes in Pima Indians. , 2003, Diabetes.
[2] S. O’Rahilly,et al. The Metabolic Syndrome: Peroxisome Proliferator-Activated Receptor γ and Its Therapeutic Modulation , 2003 .
[3] Jimmy D Bell,et al. Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma. , 2003, Diabetes.
[4] M. Laakso,et al. Effect of the Pro12Ala polymorphism in the peroxisome proliferator-activated receptor (PPAR) gamma2 gene on the expression of PPARgamma target genes in adipose tissue of massively obese subjects. , 2003, The Journal of clinical endocrinology and metabolism.
[5] T. Hayakawa,et al. PPARgamma gene polymorphism is associated with exercise-mediated changes of insulin resistance in healthy men. , 2003, Metabolism: clinical and experimental.
[6] L. Pérusse,et al. The PPAR‐gamma P12A polymorphism modulates the relationship between dietary fat intake and components of the metabolic syndrome: results from the Québec Family Study , 2003, Clinical genetics.
[7] X. Adiconis,et al. The TaqIB and −629C>A polymorphisms at the cholesteryl ester transfer protein locus: associations with lipid levels in a multiethnic population. The 1998 Singapore National Health Survey , 2002, Clinical genetics.
[8] P. Raskin,et al. Report of the expert committee on the diagnosis and classification of diabetes mellitus. , 1999, Diabetes care.
[9] Allan Vaag,et al. Impact of two common polymorphisms in the PPARgamma gene on glucose tolerance and plasma insulin profiles in monozygotic and dizygotic twins: thrifty genotype, thrifty phenotype, or both? , 2003, Diabetes.
[10] A. Morris,et al. Haplotype analysis of the PPARγ Pro12Ala and C1431T variants reveals opposing associations with body weight , 2002, BMC Genetics.
[11] M. Laakso,et al. Effect of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor gamma-2 gene on adiposity, insulin sensitivity and lipid profile in the Spanish population. , 2002, European journal of endocrinology.
[12] V. Colantuoni,et al. Fasting plasma free fatty acid concentrations and Pro12Ala polymorphism of the peroxisome proliferator‐activated receptor (PPAR) γ2 gene in healthy individuals , 2002, Clinical endocrinology.
[13] C. Weinberg,et al. Reporting, appraising, and integrating data on genotype prevalence and gene-disease associations. , 2002, American journal of epidemiology.
[14] J. Schölmerich,et al. Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma2 (PPARgamma2) is associated with higher levels of total cholesterol and LDL-cholesterol in male caucasian type 2 diabetes patients. , 2002, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.
[15] T. Jørgensen,et al. Comment: studies of the Pro12Ala polymorphism of the PPAR-gamma gene in the Danish MONICA cohort: homozygosity of the Ala allele confers a decreased risk of the insulin resistance syndrome. , 2002, The Journal of clinical endocrinology and metabolism.
[16] T. Hansen,et al. Studies of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-γ2 (PPAR-γ2) gene in relation to insulin sensitivity among glucose tolerant Caucasians , 2001, Diabetologia.
[17] F. Collins,et al. The peroxisome proliferator-activated receptor-gamma2 Pro12A1a variant: association with type 2 diabetes and trait differences. , 2001, Diabetes.
[18] M. Kasuga,et al. The Pro12 -->Ala substitution in PPAR-gamma is associated with resistance to development of diabetes in the general population: possible involvement in impairment of insulin secretion in individuals with type 2 diabetes. , 2001, Diabetes.
[19] S. O’Rahilly,et al. Evidence for gene-nutrient interaction at the PPARgamma locus. , 2001, Diabetes.
[20] J. Beilby,et al. A Pro12Ala polymorphism in the human peroxisome proliferator-activated receptor-gamma 2 is associated with combined hyperlipidaemia in obesity. , 2001, European journal of endocrinology.
[21] P. Deurenberg,et al. Can dietary factors explain differences in serum cholesterol profiles among different ethnic groups (Chinese, Malays and Indians) in Singapore? , 2001, Asia Pacific journal of clinical nutrition.
[22] D. Cox,et al. Sibling-based association study of the PPARgamma2 Pro12Ala polymorphism and metabolic variables in Chinese and Japanese hypertension families: a SAPPHIRe study. Stanford Asian-Pacific Program in Hypertension and Insulin Resistance. , 2001, Journal of molecular medicine.
[23] U. Beisiegel,et al. Association between the P12A and c1431t polymorphisms in the peroxisome proliferator activated receptor gamma (PPAR gamma) gene and type 2 diabetes. , 2001, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.
[24] S. Lien,et al. Identification of a novel peroxisome proliferator-activated receptor (PPAR) gamma promoter in man and transactivation by the nuclear receptor RORalpha1. , 2001, Biochemical and biophysical research communications.
[25] S. Chew,et al. Levels of cardiovascular disease risk factors in Singapore following a national intervention programme. , 2001, Bulletin of the World Health Organization.
[26] P. Deurenberg,et al. Validation of a semiquantitative food frequency questionnaire for estimation of intakes of energy, fats and cholesterol among Singaporeans. , 2000, Asia Pacific journal of clinical nutrition.
[27] L. Tiret,et al. The Pro12Ala polymorphism in the peroxisome proliferator-activated receptor γ2 gene is not associated with postprandial responses to glucose or fat tolerance tests in young healthy subjects: the European Atherosclerosis Research Study II , 2000, Journal of Molecular Medicine.
[28] Y. Min,et al. Significance of Pro12Ala mutation in peroxisome proliferator-activated receptor-gamma2 in Korean diabetic and obese subjects. , 2000, The Journal of clinical endocrinology and metabolism.
[29] K. Clément,et al. The Pro115Gln and Pro12Ala PPAR gamma gene mutations in obesity and type 2 diabetes , 2000, International Journal of Obesity.
[30] M. Kasuga,et al. Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-gamma 2 on thiazolidinedione-induced adipogenesis. , 2000, Biochemical and biophysical research communications.
[31] J. Auwerx,et al. Impact of the Peroxisome Proliferator Activated Receptor γ2 Pro12Ala polymorphism on adiposity, lipids and non-insulin-dependent diabetes mellitus , 2000, International Journal of Obesity.
[32] T. Kadowaki,et al. The Pro12Ala polymorphism in PPAR gamma2 may confer resistance to type 2 diabetes. , 2000, Biochemical and biophysical research communications.
[33] E S Lander,et al. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. , 2000, Nature genetics.
[34] M. Laakso,et al. Two polymorphisms in the peroxisome proliferator-activated receptor-gamma gene are associated with severe overweight among obese women. , 1999, The Journal of clinical endocrinology and metabolism.
[35] V. Colantuoni,et al. Pro12Ala substitution in the peroxisome proliferator-activated receptor-gamma2 is not associated with type 2 diabetes. , 1999, Diabetes.
[36] H. Häring,et al. The PPARγ2 amino acid polymorphism Pro 12 Ala is prevalent in offspring of Type II diabetic patients and is associated to increased insulin sensitivity in a subgroup of obese subjects , 1999, Diabetologia.
[37] S. Engeli,et al. Pro12Ala missense mutation of the peroxisome proliferator activated receptor gamma and diabetes mellitus. , 1999, Biochemical and biophysical research communications.
[38] X. L. Wang,et al. Peroxisome proliferator-activated receptor gamma C161-->T polymorphism and coronary artery disease. , 1999, Cardiovascular research.
[39] Johan Auwerx,et al. A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity , 1998, Nature Genetics.
[40] C. Yen,et al. Association of the Pro12Ala variant in the peroxisome proliferator-activated receptor-gamma2 gene with obesity in two Caucasian populations. , 1998, Diabetes.
[41] G. Gyapay,et al. Human peroxisome proliferator-activated receptor-gamma2: genetic mapping, identification of a variant in the coding sequence, and exclusion as the gene responsible for lipoatrophic diabetes. , 1998, Diabetes.
[42] J. Auwerx,et al. A genetic polymorphism of the peroxisome proliferator-activated receptor gamma gene influences plasma leptin levels in obese humans. , 1998, Human molecular genetics.
[43] J. Auwerx,et al. PPARgamma3 mRNA: a distinct PPARgamma mRNA subtype transcribed from an independent promoter. , 1998, FEBS letters.
[44] J. Auwerx,et al. The Organization, Promoter Analysis, and Expression of the Human PPARγ Gene* , 1997, The Journal of Biological Chemistry.
[45] K. Silver,et al. Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation. , 1997, Biochemical and biophysical research communications.
[46] M. Fantone,et al. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus , 1997, Diabetes Care.
[47] J Auwerx,et al. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. , 1996, Journal of lipid research.